利拉鲁肽联合二甲双胍治疗2型糖尿病临床疗效和安全性评估

摘要

Objective To evaluate the clinical efficacy and safety of liraglutide combined with metformin in curing type 2 diabetes mellitus(T2DM). Methods Total of 80 T2DM cases were randomized into liraglu-tide group(n=40) and insulin glargine group(n=40),the two groups had been chosen to take liraglutide and insulin glargine combined with metformin treatment separately for 12 weeks. The levels of fasting blood glu-cose(FBG),2 h postprandial glucose(2 h PG),and glycosy lated hemoglobin(HbA1c) were observed between groups before and after treatment,and islet β cell function(HOMA-β) and insulin resistance(HOMA-IR) were also calculated. The body mass index(BMI) and the incidence of hypoglycemia were also recorded. Results After 12 weeks of treatment,the level of FBG,2 h PG and HbA1c decreased significantly before and after treatment in the two groups(P<0. 01),but the levels had no significant difference between the two groups(P>0.05).HOMA-β was increased(P<0.01) and HOMA-IR was decreased(P<0.01) signifi-cantly from baseline in two groups, but there were no significant difference between the two groups ( P >0. 05);the BMI decreased significantly after treatment in liraglutide group(P <0. 01),and incidence of hypoglycemia was lower. Conclusion Liraglutide combined with metformin can control the blood glucose level effectively and safely in treating T2DM,and improve and enhance the islet β cell function obviously, and reduce the body weight more effectively than insulin glargine.%目的：评估利拉鲁肽联合二甲双胍治疗2型糖尿病(T2DM)的临床疗效及安全性。方法将80例T2DM患者采用随机数字表分为两组：利拉鲁肽组应用利拉鲁肽联合二甲双胍治疗(40例)和甘精胰岛素组应用甘精胰岛素联合二甲双胍治疗(40例)。治疗12周,观察两组患者治疗前后空腹血糖(FBG)、餐后2 h血糖(2 h PG)、糖化血红蛋白(HbA1c)水平,计算胰岛β细胞功能指数( HOMA-β)和胰岛素抵抗指数( HOMA-IR),以及体质指数( BMI)和低血糖发生情况等。结果治疗后两组患者FBG、2 h PG和HbA1c与治疗前相比均显著降低(P<0．01),但组间比较差异无统计学意义(P>0．05)；治疗后HOMA-β较治疗前明显升高(P<0．01),HOMA-IR明显降低(P<0．01),但组间比较差异无统计学意义(P>0．05)；治疗后利拉鲁肽组的BMI明显降低,与治疗前相比差异有统计学意义(P<0．01),且低血糖发生率较低。结论利拉鲁肽联合二甲双胍治疗T2DM具有良好的临床疗效和安全性,能够明显改善患者胰岛β细胞功能,比甘精胰岛素更能有效地降低患者增加的体质量。